(CIHR) Project Grant worth $1,109,250 To further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD).
The CIHR grant entitled “A Multifaceted Function for Dipeptidase-1 in Kidney Injury” was awarded to a research team at the University of Calgary led Dr. Daniel Muruve. Dr. Muruve is also the Chief Science Officer of Arch. The new grant will help further understand the novel mechanism of action for DPEP-1 in kidney inflammation and its impact on CKD.
Quote from Dr. Daniel Muruve:
“The cause of kidney disease is generally unknown and as a result, there are currently few treatments for acute kidney injury (AKI) or CKD. The only treatment for kidney failure, at present, is life support using dialysis or kidney transplantation. A better approach is to find new treatments for AKI and CKD that prevent kidney failure altogether. We have strong evidence that inflammation and DPEP-1 play very important roles in kidney injury and disease. We plan to study exactly how DPEP-1 contributes to kidney disease, including CKD and how to best target its function therapeutically.”